Hims & Hers Health

HIMS

Market cap $14.2B

Shares of Hims & Hers (HIMS 16.20%) jumped 9% in trading on Wednesday after the company announced an expansion into menopause and perimenopause specialties on the Hers app. This is the kind of product expansion that will drive greater adoption and higher growth long term, as Travis Hoium highlights in this video.

Healthcare products specialist Hims & Hers Health (HIMS 16.20%) stock passed the most crucial exam of all on Wednesday, as investors gave it the thumbs-up. The shares ended the day more than 16% higher in price, thanks to the company's reveal that it's pushing into a potentially lucrative new segment.

Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.

The company expects the new specialty to help the Hers unit to surpass $1 billion in annual revenue next year.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to affordable treatment plans built specifically for women experiencing perimenopause and menopause. Starting today, women can work with a provider on the platform to access treatment plans tailored to their health history and personal preferences. There is a clear gap in health care access for women.

Hims & Hers Health said it is now providing menopause care, marking the company's latest push into hormone-replacement therapies.

HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.

These two healthcare companies are interesting choices for long-term investors, but only one can be the better investment in this comparison.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 3, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refe.

I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aiming for 30%+ growth in 2026. Despite a temporary dip into negative free cash flow, HIMS maintains strong profitability targets and trades at an attractive 24x forward free cash flow.